for people with PNH

Learn More
Fearlessly Advancing


the first potential treatment
in geographic atrophy

Learn More
Leaders in Complement


at the forefront of targeted
C3 therapies

Learn More

With courageous science, creativity, and compassion,
we are committed to delivering therapies for people with
complement-driven diseases.

About Us
Folded page of a newspaper

Latest news

November 12, 2021

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback

November 10, 2021

Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting

November 8, 2021

Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results

A man with a baby in a baby carrier

At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

Our groundbreaking science

targeting C3 offers the potential to provide comprehensive control of complement, a part of the immune system

Our Science
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

We aim to transform

treatment across a broad range of debilitating diseases driven by complement